Sickle Cell Disease Trial, Recruiting (NCT05170412)

Sickle Cell Disease Trial, Recruiting NCT05170412 Sponsor: National Institutes of Health Clinical Center (CC) Condition: Sickle Cell Disease

Printed from Voxsanity (voxsanity.com.au) — NCT05170412 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Sickle Cell Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are willing to take part in all parts of the study for its entire duration
You are 18 years of age or older at the time of signing up
You have been officially diagnosed with Sickle Cell Disease (SCD), confirmed through your medical records, or have one of the following specific genetic types of the condition: HbSS, HbSC, HbSβ0, or HbSβ+ (confirm with trial site if unsure which type you have)

Who may not be able to join:

You are under 18 years of age
You are not able to speak, read, write, or understand English
You have a condition or illness that would prevent you from being able to fully understand and agree to take part in the study, such as a cognitive impairment
You carry the sickle cell trait rather than having sickle cell disease (these are different — confirm with trial site if you are unsure which applies to you)
You are currently admitted to a hospital for treatment of SCD at the time of signing up
You are currently pregnant at the time of signing up

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 22 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Nicole M Farmer, M.D., National Institutes of Health Clinical Center (CC)

Phone: (240) 927-2603

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05170412

Sponsor: National Institutes of Health Clinical Center (CC)

Phase: Not Applicable

Status: Recruiting

Condition: Sickle Cell Disease

Trial contact: (240) 927-2603

More information: https://clinicaltrials.gov/study/NCT05170412

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are willing to take part in all parts of the study for its entire duration
You are 18 years of age or older at the time of signing up
You have been officially diagnosed with Sickle Cell Disease (SCD), confirmed through your medical records, or have one of the following specific genetic types of the condition: HbSS, HbSC, HbSβ0, or HbSβ+ (confirm with trial site if unsure which type you have)

Who may not be able to join:

You are under 18 years of age
You are not able to speak, read, write, or understand English
You have a condition or illness that would prevent you from being able to fully understand and agree to take part in the study, such as a cognitive impairment
You carry the sickle cell trait rather than having sickle cell disease (these are different — confirm with trial site if you are unsure which applies to you)
You are currently admitted to a hospital for treatment of SCD at the time of signing up
You are currently pregnant at the time of signing up

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 22 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

National Institutes of Health Clinical Center (CC)

Registry

ClinicalTrials.gov

Start date

26 May 2022

Est. completion

31 December 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

assess the dietary intake and behaviors of outpatient adults with SCD

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov